This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
After reading the editorial, "Clonazepam: A New Anticonvulsant" (235:1480, 1976), I am compelled to write, "Shame on the editor emeritus." The fifth paragraph of his otherwise satisfactory editorial contains the following: "The drug (clonazepam) is not approved by the FDA for treatment of grand mal, partial seizures with complex symptoms... or focal seizures."The fact is that the Food and Drug Administration (FDA) has no legal authority to approve uses of drugs that it sanctions for marketing. The FDA can approve only a drug's labeling, which may or may not recommend uses. If the FDA had the degree of authority attributed to it by the editor emeritus, lidocaine hydrochloride, for example, would never have been used in patients with cardiac arrhythmias, and propranolol hydrochloride probably would not be available for treating angina pectoris.
David NF. FDA Authority Questioned. JAMA. 1976;235(20):2191. doi:10.1001/jama.1976.03260460015011
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: